Skip to Content
Merck
  • The enantioselective determination of chlorpheniramine and its major metabolites in human plasma using chiral chromatography on a beta-cyclodextrin chiral stationary phase and mass spectrometric detection.

The enantioselective determination of chlorpheniramine and its major metabolites in human plasma using chiral chromatography on a beta-cyclodextrin chiral stationary phase and mass spectrometric detection.

Journal of pharmaceutical and biomedical analysis (2002-01-05)
Karen M Fried, Andrea E Young, Sally Usdin Yasuda, Irving W Wainer
ABSTRACT

A sensitive enantioselective high-performance liquid chromatographic (HPLC) method has been developed for the simultaneous determination of plasma concentrations of (-)(R)- and (+)(S)-chlorpheniramine (CP) and their metabolites, desmethyl-chlorpheniramine (DCP), didesmethyl-chorpheniramine (DDCP) and chlorpheniramine N-oxide (CPNO). Enantioselective separations were achieved on a beta-cyclodextrin chiral stationary phase (CYCLOBOND I 2000) with a mobile phase consisting of diethylamine acetate (0.25%, pH 4.4):methanol:acetonitrile [85:7.5:7.5, (v/v/v)]and a flow-rate of 0.5 ml/min. For CP, the enantioselectivity (alpha) of the separation was 1.12 with a resolution factor (R(s)) of 1.17. The method was validated for CP by using mass spectroscopy detection (MSD). Concentrations of each enantiomer could be measured down to 125 pg/ml from a 1-ml plasma sample. Extracted calibration curves were linear from 0.13 to 50.00 ng/ml for each enantiomer. The method was applied to samples from two clinical studies.

MATERIALS
Product Number
Brand
Product Description

Supelco
Astec® CYCLOBOND I 2000 Chiral HPLC Column, 5 μm particle size, L × I.D. 10 cm × 2.1 mm
Supelco
Astec® CYCLOBOND I 2000 Chiral HPLC Column, 5 μm particle size, L × I.D. 25 cm × 4.6 mm
Supelco
Astec® CYCLOBOND I 2000 Chiral HPLC Column, 5 μm particle size, L × I.D. 15 cm × 2.1 mm
Supelco
Astec® CYCLOBOND I 2000 Chiral HPLC Column, 5 μm particle size, L × I.D. 25 cm × 10 mm